(IN BRIEF) After over a decade of leading the MRC-University of Glasgow Centre for Virus Research (CVR), Professor Massimo Palmarini is stepping down as Director to take on the role of Head of Viroscience at Erasmus University Medical Centre in … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged apppointment, COVID-19, cross-species transmission, cryo-EM microscopes, CVR, drug-resistance screening hub, Ebola, Emerging Infectious Diseases, Erasmus University Medical Centre, global virus research, Head of Viroscience, hepatitis, human-animal interface, influenza, leadership, Medical Research Council, MRC, MRC-University of Glasgow Centre for Virus Research, Professor Emma Thomson, Professor Iain McInnes, Professor Massimo Palmarini, public health, University of Glasgow, vaccine trials, viral diseases, viral sequencing, virus pathogenesis, ZIKA
(IN BRIEF) FluMist, a needle-free nasal spray influenza vaccine, has been approved by the FDA for self-administration in the US, making it the first flu vaccine of its kind to be used at home. Adults up to 49 years old … Read the full press release
(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annaliesa Anderson, BioNTech, Combination Vaccine, Comirnaty, COVID-19, influenza, influenza A, influenza B, mRNA, partnership, Pfizer, Prof. Ugur Sahin, respiratory diseases, SARS-CoV-2 strains, sustainability, wellness
(IN BRIEF) AstraZeneca is set to present new data at the 12th annual IDWeek conference, emphasizing the role of long-acting antibodies and vaccines in safeguarding at-risk individuals from common infectious respiratory diseases. The company will share 15 abstracts, including oral … Read the full press release
(PRESS RELEASE) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, has announced that the European Commission has approved Xofluza (baloxavir marboxil), a … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged CHILDREN, infectious disease, influenza, influenza antiviral drug, Levi Garraway, oseltamivir, prevention, Roche, Xofluza treatment
(COMUNICADO DE PRENSA) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionero mundial en productos farmacéuticos y diagnóstico centrado en el avance de la ciencia para mejorar la vida de las personas, ha anunciado que la … Read the full press release
Researchers at the University of Cambridge and the University of Oxford have discovered a new molecule that plays a key role in the immune response that is triggered by influenza infections. The molecule, a so-called mini viral RNA, is capable … Read the full press release
Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in high-risk patients Influenza, or “flu,” represents a serious threat … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged baloxavir marboxil, flu, influenza, Roche, Sandra Horning
Coventry, UK, 08-Jan-2018 — /EuropaWire/ — VirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has won non-dilutive funding worth up to $4.2 million from the US Defense Advanced Research Projects Agency (DARPA). … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?